BIT

0.00%

3.3¢ biotron limited

Major Article - BIT225, in combination with 3-drug antiretroviral therapy, page-194

First 194 Last

Share
Profile

Follow
J8

14,533 Posts.

821

30/10/20

01:47

Post #: 48509714
Share

Originally posted by Colingray ↑

Similarities between the effect of SARS-CoV-2 and HCV on the cellular level, and the possible role of ion channels in COVID19 progression: a review of potential targets for diagnosis and treatment

https://www.tandfonline.com/doi/full/10.1080/19336950.2020.1837439

Therapies targeted at the p7 ion channel

p7, similar to SARS-CoV-2 E protein, is an HCV protein that plays a role in viral assembly and release of mature virions. In addition to this, the p7 protein is conserved across all genotypes of HCV, making it a potentially effective therapeutic target for HCV....A recent study, however, discovered that amantadine and its new analogue, rimantadine, are too small to fit the binding pocket of p7 and may not be as effective in vivo [50]. Developing a larger analogue of these inhibitors may thus help circumvent this potential setback and prove useful for SARS-CoV-2 treatment.

Amiloride is a guanidium compound that functions to block the Na+ channel in epithelial tissues to facilitate Na reabsorption in the kidney in a manner that depletes Na but not K within the body. Amiloride has been shown previously to inhibit release of viral particles in the Vpu protein of HIV-1 via inhibition of the ion channel activity that results from the virus budding [51]. Vpu has also been shown to be similar to p7 of HCV, which has prompted the investigation of amiloride activity in terms of its ability to inhibit p7. A molecular dynamic modeling study has shown that a derivative of amiloride BITT225 has strong hydrophobic interaction with p7, which may translate to in vivo inhibition of p7 [52]. However, this remains to be tested in human studies. (my note: I assume human studies refers to Covid-19)

I've been away for a bit, so I don't know if this article has been posted yet from the 12th Oct. Goes into great detail about the similarities of Covid-019 and HCV. As we know BIT has had a strong focus on HCV and now Covid, and the interaction shows how BIT appear to be on the right track for a successful outcome for both (and more)

Expand

Colin Gray
As usual, your research skills are second to none.

HepC drugs have been under much investigation after an Iranian group worked on some similar theories. Albeit not P7 inhibitors.

I posted earlier about this Iranian trial and the potential of Daclatasvir.

Daclatasvir is the drug that I took (alongside Sofosbuvir) to CURE my HCV.

Here is a link to a publication that my friends Hill and Freeman were a part of. Some here will find it interesting, some will still have no idea.

https://academic.oup.com/jac/article/75/11/3366/5889946

Last edited by J8: 30/10/20

BIT Price at posting: 8.4¢ Sentiment: None Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Bitcoin investors need to know the risks

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

There are more pages in this discussion • 28 more messages in this thread...

First 194 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 3.3¢		Change 0.000(0.00%)		Mkt cap ! $29.77M

Open	High	Low	Value	Volume
3.4¢	3.4¢	3.1¢	$74.61K	2.300M

Buyers (Bids)

No.	Vol.	Price($)
4	280031	3.2¢

Sellers (Offers)

Price($)	Vol.	No.
3.4¢	96500	1

View Market Depth

No.	Vol.	Price($)
3	264406	0.032
4	227980	0.031
9	585666	0.030
1	100000	0.029
3	153000	0.028

Price($)	Vol.	No.
0.035	308000	2
0.036	65500	1
0.037	537816	2
0.039	430546	2
0.040	133240	3

Last trade - 15.22pm 12/07/2024 (20 minute delay)

BIT (ASX) Chart

Major Article - BIT225, in combination with 3-drug antiretroviral therapy, page-194

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Bitcoin investors need to know the risks

Nimy to raise $1.21M to explore 'newsy' WA targets

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Immutep reports strong response rate from immunotherapies treating carcinomas

Almonty locks in govt agreement for tungsten oxide plant in South Korea

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Major Article - BIT225, in combination with 3-drug antiretroviral therapy, page-194

Top Stories

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Bitcoin investors need to know the risks

Nimy to raise $1.21M to explore 'newsy' WA targets

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Immutep reports strong response rate from immunotherapies treating carcinomas

Almonty locks in govt agreement for tungsten oxide plant in South Korea

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News